Mirum Pharmaceuticals, Inc.
MIRM
$67.72
-$2.37-3.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -41.42M | -58.56M | -77.34M | -87.94M | -99.81M |
| Total Depreciation and Amortization | 25.58M | 25.57M | 25.37M | 24.98M | 23.69M |
| Total Amortization of Deferred Charges | 1.72M | 1.70M | 1.68M | 1.66M | 1.64M |
| Total Other Non-Cash Items | 66.21M | 61.05M | 56.09M | 49.03M | 56.43M |
| Change in Net Operating Assets | -7.39M | -20.77M | -12.65M | 22.59M | 16.83M |
| Cash from Operations | 44.69M | 9.00M | -6.85M | 10.33M | -1.23M |
| Capital Expenditure | -374.00K | -368.00K | -1.02M | -993.00K | -973.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -23.95M | -39.76M | -105.23M | -89.13M | -91.79M |
| Cash from Investing | -24.32M | -40.13M | -106.25M | -90.13M | -92.77M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 36.48M | 24.25M | 22.85M | 17.70M | 14.42M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -281.00K |
| Cash from Financing | 36.48M | 24.25M | 22.85M | 17.70M | 14.14M |
| Foreign Exchange rate Adjustments | 2.25M | 1.99M | -355.00K | -1.30M | 190.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 59.11M | -4.89M | -90.60M | -63.40M | -79.67M |